GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test could spare stomach cancer patients from unnecessary chemo
Disease control Not yet recruitingThis study tests whether a simple blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide which stomach cancer patients need extra chemotherapy after surgery. About 304 people with locally advanced stomach cancer will be randomly assigned to either standard…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells take on stomach cancer in new trial
Disease control Not yet recruitingThis early-phase trial is testing a new treatment called CT0494BCP CAR-T cells in 50 adults with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified in a lab to bette…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Shot vs. IV: could a simple injection improve stomach cancer treatment?
Disease control Not yet recruitingThis study compares two ways of giving the immunotherapy drug AK104 alongside standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. One group gets AK104 as a shot under the skin (subcutaneous), the other as a…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for stomach cancer: immunotherapy combo targets resistant tumors
Disease control Not yet recruitingThis phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do …
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combo shows promise in shrinking aggressive stomach tumors before surgery
Disease control Not yet recruitingThis study tests a new drug called zanidatamab, given with chemotherapy before surgery, for people with a specific type of stomach or gastroesophageal junction cancer that has high levels of HER2 protein. The goal is to see if this combination can shrink tumors more effectively t…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Blood test may spare gastric cancer patients from unnecessary chemo
Disease control Not yet recruitingThis study tests whether a simple blood test that detects tiny traces of cancer DNA can guide treatment decisions after gastric cancer surgery. About 90 patients will have their blood tested after surgery, and those with no detectable cancer DNA may safely skip additional chemoth…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug cocktail aims to tackle tough gut cancers
Disease control Not yet recruitingThis Phase 2 trial will test an experimental drug called SSGJ-706 combined with standard chemotherapy (and sometimes another drug, bevacizumab) in 300 people with advanced gastrointestinal cancers that cannot be surgically removed. The goal is to see if the combination is safe an…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Stomach cancer breakthrough: study seeks best Post-Surgery care for complete responders
Disease control Not yet recruitingThis study looks at 500 stomach cancer patients who had chemotherapy plus immunotherapy before surgery and achieved a complete response (no cancer left in the removed tissue). It compares different post-surgery treatments, including chemotherapy alone or with immunotherapy, to se…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Liaoning Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 14:31 UTC
-
Stomach cancer study may spare some patients unnecessary surgery
Knowledge-focused Not yet recruitingThis study looks at whether a tumor's DNA repair status (MMR) changes how well the presence of cancer cells in lymph vessels predicts spread to lymph nodes in stomach cancer. Researchers will review medical records of 3,000 patients who had surgery. The goal is to improve risk as…
Matched conditions: GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC